# US 2025/0367193 A1 · Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367193 A1
- Document ID: US20250367193A1
- Status: Published application
- Kind: A1
- Application number: 18/875,614
- Filed: 2023-06-21
- Published: 2025-12-04
- Earliest claimed: 2022-06-22
- Assignees: Nikang Therapeutics, Inc.
- Applicants: Nikang Therapeutics, Inc.
- Inventors: Yan LOU; Zhiyong YU
- Web page: https://patentgrep.com/patent/US20250367193A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07D 401/14: containing three or more hetero rings
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

## Claims

### Claim 1

A compound of Formula (IA′):
wherein:
Degron is an E3 ligase ligand selected from:
(a) a group of formula (i):
(b) a group of formula (ii):
(c) a group of formula (iii):
(d) a group of formula (iv):
(e) a group of formula (v):
and
(f) a group of formula (vi):
where:
Rx is hydrogen, alkyl, cycloalkyl, or alkylcarbonyloxy;
Ya is CH or N;
Za is a bond, —CH2—, —NH—, O, or —NHC(O)— where NH of —NHC(O)— is attached to Ya;
ring A of the E3 ligase ligand of formula (i) is a group of formula (a), (b), or (c):
where:
Raa, Rbb, Rcc, and Rdd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;
R4 and R5 are independently hydrogen or alkyl; or R4 and R5 together with the carbon to which they are attached form >C═O; and
R6 is hydrogen or alkyl;
ring B of the E3 ligase ligand of formula (ii) is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with Ree and Rff independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; and
X1, X2, X3 and X4 are independently a bond, -alkylene-, —O—, —(O-alkylene)-, -(alkylene-O)—, —(NRgg-alkylene)-, -(alkylene-NRhh)—,
—NH—, —N(alkyl)-, —C(═O)—, —NRjjC(═O)—, or —C(═O)NRkk— where Rgg, Rhh, Rjj, and Rkk are independently hydrogen, alkyl, or cycloalkyl and each alkylene is optionally substituted with one or two fluoro;
Ry is alkyl, hydroalkyl, cycloalkyl or heterocyclyl wherein cycloalkyl and heterocyclyl are substituted with Ra selected from hydrogen, halo, cyano, alkylcarbonyl, and alkylcarbonylamino; and
Wa is bond, O, S, or alkylene;
Hy is cycloalkylene, arylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with Rb, Rc, and Rd independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;
R is alkyl, halo, haloalkyl, cycloalkyl, or cyano;
Q1 is a bond, —O— or —N(R1)— where R1 is hydrogen or alkyl;
Q2 is a bond or alkylene;
ring J is aryl, heteroaryl, cycloalkyl, spiro cycloalkyl, fused cycloalkyl, bridged cycloalkyl, heterocyclyl, spiro heterocyclyl, fused heterocyclyl, or bridged heterocyclyl, provided that when Q1 and Q2 are bond, and ring J is heteroaryl, then the heteroaryl of ring J is other than pyrazolyl and imidazolyl substituted with R1a, R2a, R3a, and R4a;
R1a, R2a, R3a, and R4a are independently selected from hydrogen, deuterium, alkyl, alkylidenyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, hydroxy, alkoxy, cyano, hydroxyalkyl, aralkyl, heteroaralkyl, amino, heterocyclyl, or heterocyclylalkyl, wherein the cycloalkyl, heterocyclyl, and the ring portion of cycloalkylalkyl, aralkyl, and heterocyclylalkyl are substituted with Re, Rf, and Rg independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, cycloalkyl, cyano, hydroxy, amino, alkoxy, acyl, aminocarbonyl, and carboxy; and
L is —Z1—Z2—Z3—Z4—Z5—Z6— where:
Z1 is a bond, alkylene, —C(O)NR—, —NR′(CO)—, —S(O)2NR—, —NR′S(O)2—, —(O-alkylene)a-, -(alkylene-O)a—, phenylene, monocyclic heteroarylene, or heterocyclylene, where each ring is substituted with Rh and Ri independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
Z2 is a bond, alkylene, alkynylene, —C(O)—, —C(O)N(R)—, —NR′(CO)—, —(O-alkylene)b-, -(alkylene-O)b—, —O(CH2)7—, —O(CH2)8—, cycloalkylene, or -heterocyclylene, where each ring is substituted with Rj and Rk independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
Z3 is a bond, alkylene, alkynylene, —C(O)NR—, —NR′(CO)—, —O—, —NR″—, —(O-alkylene)c-, -(alkylene-O)c—, cycloalkylene, spiro cyclolalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, or 11 to 13 membered spiro heterocyclylene, where each ring is substituted with Rm and Rn independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
Z4 is a bond, alkylene, alkynylene, -(alkylene-NR″)—, —O—, —C(O)—, —NR″—, —(O-alkylene)a-, -(alkylene-O)a—, cycloalkylene, spiro cyclolalkylene, phenylene, heteroarylene, heterocyclylene, fused heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Ro and Rp independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;
Z5 is a bond, -alkylene, —NR″—, —O—, —C(O)—, —S(O)2—, —NR′(CO)—, —C(O)NR—, phenylene, monocyclic heteroarylene, or heterocycylene, where each ring is substituted with Rq and Rr independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy, and
Z6 is a bond, alkylene, —NR″—, —O—, -(alkylene-O)—, —C(O)—, —S(O)2—, —NR′(CO)—, or —C(O)NR—;
where each R, R′ and R″ is independently hydrogen or alkyl, each a, b, c, and d is independently an integer selected from 1 to 6, and each alkylene of —Z1—, —Z2—, —Z3—, —Z4—, —Z5— and —Z6— is substituted with Rs and Rt where Rs is hydrogen and deuterium and Rt is hydrogen, deuterium, haloalkyl, hydroxy, alkoxy, cyano, cycloalkyl, heterocyclyl, aryl, or monocyclic heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, monocyclic heteroaryl are substituted with one or two substituents independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, or cyano; provided that at least one of —Z1—Z2—Z3—Z4—Z5—Z6— is not a bond; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
—Z5— is
substituted with Rq and Rf; and
Z6 is —S(O)2—.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X1, X2, X3, X4, Z1, and Z2 are each a bond;
Z3 is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Rm and Rn independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
Z4 is alkylene, —O—, cycloalkylene, or heterocyclylene, where each ring is substituted with Ro and Rp independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino, preferably hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
Z5 is phenylene or monocyclic heteroarylene, each ring substituted with Rq and Rr independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy; and
Z6 is —S(O)2—; and
wherein alkylene is substituted with Rs and Rt.

### Claim 4 (depends on 1, 2)

The compound of claim 1, 2, or 3, or a pharmaceutically acceptable salt thereof, wherein —Z3—Z4—Z5—Z6— is:
wherein Rq, Rm, and Rn are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein —Z3—Z4—Z5—Z6— is:
wherein each of Rq and Rm are independently selected from hydrogen, methyl, fluoro, chloro, cyano, methoxy, difluoromethoxy, cyclopropyl, difluoromethyl, and trifluoromethyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R is haloalkyl.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R is trifluoromethyl or 2,2,2-trifluoroethyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein ring J is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein ring J is cyclopentyl or cyclohexyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein Hy is heterocyclylene, phenylene, spiro heterocyclylene, or cycloalkylene, wherein each of the aforementioned rings is substituted with Rb, Rc, and Rd where Rb and Rc are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, and hydroxy and Rd is hydrogen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Hy is
where the N atom of the piperidin-1,4-diyl ring is attached to L.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein the Degron is an E3 ligase ligand of formula (i) where ring A:

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein Degron is the E3 ligase ligand selected from:
where Ree is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and Rff is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating cancer in a patient which method comprises administering to the patient in recognized need thereof, a therapeutically effective amount a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or with a pharmaceutical composition of claim 14.

### Claim 16 (depends on 15)

The method of claim 15, wherein a) the compound, or a pharmaceutically acceptable salt thereof, or b) the pharmaceutical composition is administered in combination with at least one other anticancer agent.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the cancer is lung cancer, skin cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus, endometrial cancer, gastric cancer, head and neck cancer, liver cancer, ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, or parathyroid cancer.
